Cough News and Research RSS Feed - Cough News and Research

Neos Therapeutics completes private financing round, raises $15.5M

Neos Therapeutics, Inc. ("Neos" or "the Company"), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed an oversubscribed round of private financing, raising a total of $15.5 million. [More]
Brief physical therapy improves symptoms, QoL in urinary incontinence

Brief physical therapy improves symptoms, QoL in urinary incontinence

A 1-month programme of physical therapy results in significant improvements in quality of life among women with urinary incontinence, a clinical trial has found. [More]
Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

Brisbane's water supply has been found to contain disease carrying bugs which can be directly linked to infections in some patients, according to a new study by QUT. [More]

NHB announces new partnership with 3-time Gold Medalist Kerri Walsh Jennings

In an effort to increase awareness of the multi-faceted benefits of honey, the National Honey Board (NHB) announced a new partnership today with 3-time Gold Medalist Kerri Walsh Jennings, of beach volleyball fame. [More]

Advanced age should not preclude sunitinib use for mRCC

Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows. [More]

Mini-sling partially successful for stress urinary incontinence

A mini-sling that requires a single incision may be a viable alternative to the “gold standard” transobturator midurethral sling for the treatment of stress urinary incontinence, a randomised controlled trial has found. [More]
Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend. [More]
Research roundup: Examining readmissions; easing doctor burnout

Research roundup: Examining readmissions; easing doctor burnout

Despite massive early IT problems, exchange enrollment is accelerating rapidly. While enrollment may not reach 7 million by the end of March, we expect at least 5 million to have enrolled by the close of the initial open-enrollment period. If enrollment falls far short, HHS could extend open enrollment for a fixed period to reach its 7 million target. ... We project that 5 million new beneficiaries will be covered by Medicaid and the Children's Health Insurance Program by the end of 2014. Medicaid managed-care enrollment of non-dual beneficiaries will increase by 20 percent from 2013 to 2014 and by 38 percent from 2013 to 2016. We expect that 75 percent of non-dual Medicaid beneficiaries will be covered by Managed Care Organizations starting in 2015, up from 63 percent in 2012 (Feb. 2014). [More]

TPI announces financial results for second quarter fiscal year 2014

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter fiscal year 2014. [More]
Manchester researchers become first in world to assess all genetic links with fungal lung infection CPA

Manchester researchers become first in world to assess all genetic links with fungal lung infection CPA

​A grandfather-of-three from Tameside is helping University of Manchester researchers become the first in the world to assess all the genetic links with Chronic Pulmonary Aspergillosis (CPA) - a debilitating fungal lung infection that claims the lives of thousands of people in the UK and millions more worldwide. [More]
Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists' training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise. [More]
Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients. [More]

URTI risk factor for chronic, recurrent otitis media

Results from a meta-analysis indicate that upper respiratory tract infection increases the odds of chronic or recurrent otitis media over sixfold. [More]
Addressing antibiotic resistance: an interview with Professor Otto Cars, Uppsala University, Sweden

Addressing antibiotic resistance: an interview with Professor Otto Cars, Uppsala University, Sweden

Antibiotic resistance is a consequence of antibiotic use. Bacteria adapt to the threat of antibiotics using mechanisms to overcome the drug. These bacteria, which we call resistant bacteria, then survive. [More]
CDC recommends effective tips to help families stay healthy during peak flu activity

CDC recommends effective tips to help families stay healthy during peak flu activity

With outbreaks of cold and flu on the rise across the U.S., Americans are facing a seemingly impossible task of helping their families stay healthy this winter. As of last week, the U.S. Centers for Disease Control and Prevention (CDC) reported that 47 states have declared the incidence of flu to be regional or widespread in their communities and nearly 10,000 cases of H1N1 have been documented. [More]
E.R. expert warns public about 5 things doctor may do wrong when treating for flu

E.R. expert warns public about 5 things doctor may do wrong when treating for flu

The flu season is in full swing starting mostly in the second week of January when emergency rooms are more busy than usual with patient with flu like symptoms. Dr. James Kojian, E.R. expert and founder of DRTOHELP.COM, warns the public about five things your doctor may be doing wrong when treating for the flu. [More]

FDA to make recommendations on safety of oral tablets used to treat ragweed allergy symptoms

There is more to seasonal allergies than a little congestion and sneezing. If you notice eating watermelon, cantaloupe or avocado make you cough and itch, it may be a symptom of ragweed allergy. But more help might be on the way for some of the 23 million hay fever sufferers. [More]

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces positive top-line results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease. [More]
Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Gastroesophageal Reflux Disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. [More]
Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma. [More]